amantadine and selegiline

amantadine has been researched along with selegiline in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (14.75)	18.7374
1990's	20 (32.79)	18.2507
2000's	21 (34.43)	29.6817
2010's	11 (18.03)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Ahman, M; Holmén, AG; Wan, H	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Camins, A; Camps, P; Duque, MD; Kelly, JM; López-Querol, M; Prathalingam, SR; Sureda, FX; Torres, E; Valverde, E; Vázquez, S	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Gozalbes, R; Pineda-Lucena, A	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Siemers, E	1
Chan, WW; Rausch, WD; Riederer, P; Schallauer, E; Weiser, M	1
Jacobs, MB; Varon, J	1
George, CF; Robertson, DR	1
Goetz, CG; Klawans, HL; Rajput, AH; Tanner, CM; Thiessen, B; Uitti, RJ	1
Birkmayer, W	1
Aminoff, MJ	1
Wirz, D	1
Weiner, M	1
Lang, AE	1
Colucci d'Amato, C; Cristillo, A; Puccini, A; Vizioli, R	1
Quinn, NP	1
Ghika, J	1
Janjua, R; Roos, RA; van Kempen, GM	1
Sweeney, PJ	1
Danysz, W; Quack, G; Rogoz, Z; Skuza, G	1
Quinn, N	1
Callender, TJ; Morrow, L; Subramanian, K	1
Brownlee, HJ; Stacy, M	1
Kishore, A; Snow, BJ	1
Ajax, T; Dobson, J; Rodnitzky, R	1
Calne, DB	1
Oertel, WH; Quinn, NP	1
Hagell, P; Odin, P; Vinge, E	1
De Weerdt, W; Dom, R; Lesaffre, E; Nieuwboer, A	1
Ruggieri, S; Silver, DE	1
Morris, K	1
Ahlskog, JE	1
Damier, P	1
Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA	1
Cullen, N; Lexell, J; Zafonte, RD	1
Gille, G; Müller, T; Przuntek, H; Reichmann, H; Riederer, P; Riess, O; Schwartz, A; Schwarz, J; Vogt, T	1
Okamoto, K; Tanaka, M	1
Kurlan, R	1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C	1
Waters, C	1
Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G	1
Brodsky, MA; Koudelka, C; Swarztrauber, K	1
Dell'Antone, P; Drago, D; IbnLkayat, M; Zatta, P	1
Klivényi, P; Vécsei, L	1
Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U	1
Galgóczy, L; Papp, T; Tóth, L; Vágvölgyi, CS; Virágh, M	1
Sheehan, J; Thorpe, M; Wilson, L	1
Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K	1
Canning, SD; Wang, XP; Zhang, LL	1

Reviews

23 review(s) available for amantadine and selegiline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Recent progress in the treatment of Parkinson's disease. Comprehensive therapy, 1992, Volume: 18, Issue:9 Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1992
Drug therapy for Parkinson's disease in the elderly. British medical bulletin, 1990, Volume: 46, Issue:1 Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1990
Update on the treatment of Parkinson's disease. Connecticut medicine, 1985, Volume: 49, Issue:10 Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors	1985
Update on antiparkinsonian agents. Geriatrics, 1982, Volume: 37, Issue:9 Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance	1982
[Biochemical bases of Parkinson disease]. Recenti progressi in medicina, 1984, Volume: 75, Issue:10 Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Selegiline; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase	1984
Anti-parkinsonian drugs today. Drugs, 1984, Volume: 28, Issue:3 Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline	1984
Parkinson's disease: managing symptoms and preserving function. Geriatrics, 1995, Volume: 50, Issue:9 Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combinations; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Selegiline	1995
Drug treatment of Parkinson's disease. BMJ (Clinical research ed.), 1995, Mar-04, Volume: 310, Issue:6979 Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1995
Treatment options for early Parkinson's disease. American family physician, 1996, Volume: 53, Issue:4 Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline	1996
Drug management of Parkinson's disease. Canadian family physician Medecin de famille canadien, 1996, Volume: 42 Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl	1996
Early idiopathic parkinsonism: initiation and optimization of treatment. Clinical neuropharmacology, 1994, Volume: 17 Suppl 2 Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline	1994
Parkinson's disease: drug therapy. Bailliere's clinical neurology, 1997, Volume: 6, Issue:1 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome	1997
Pregnancy in Parkinson's disease: a review of the literature and a case report. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline	1998
Initiating therapy for Parkinson's disease. Neurology, 1998, Volume: 50, Issue:6 Suppl 6 Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline	1998
Medical treatment of later-stage motor problems of Parkinson disease. Mayo Clinic proceedings, 1999, Volume: 74, Issue:12 Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone	1999
[What strategies are recommended for early stage disease? Other treatments]. Revue neurologique, 2000, Volume: 156 Suppl 2 Pt 2 Topics: Amantadine; Antioxidants; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline	2000
Possible applications for dopaminergic agents following traumatic brain injury: part 2. The Journal of head trauma rehabilitation, 2001, Volume: 16, Issue:1 Topics: Amantadine; Benzophenones; Benzothiazoles; Brain Injuries; Catechols; Dopamine Agents; Humans; Indoles; Neuroprotective Agents; Nitriles; Nitrophenols; Patient Selection; Pramipexole; Selegiline; Thiazoles; Tolcapone	2001
Practical importance of neuroprotection in Parkinson's disease. Journal of neurology, 2002, Volume: 249 Suppl 3 Topics: Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Selegiline	2002
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5 Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone	2005
Other pharmacological treatments for motor complications and dyskinesias. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11 Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline	2005
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. Fortschritte der Neurologie-Psychiatrie, 2010, Volume: 78 Suppl 1 Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline	2010
Freezing of Gait in Parkinsonism and its Potential Drug Treatment. Current neuropharmacology, 2016, Volume: 14, Issue:4 Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome	2016

Trials

1 trial(s) available for amantadine and selegiline

Article	Year
Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1 Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome	2006

Article

Year

Efficacy and safety of high-dose cabergoline in Parkinson's disease.

Acta neurologica Scandinavica, 2006, Volume: 113, Issue:1

Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome

2006

Other Studies

37 other study(ies) available for amantadine and selegiline

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2 Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6 Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1 Topics: Amines; Animals; Antiparkinson Agents; Cells, Cultured; Humans; Memantine; Molecular Structure; Neurons; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis	2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
QSAR-based solubility model for drug-like compounds. Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19 Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water	2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism. Journal of neural transmission. Supplementum, 1990, Volume: 32 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Interactions; Female; Gerbillinae; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Parkinson Disease, Secondary; Selegiline; Serotonin	1990
Treating the progressive stages of Parkinson's disease. Postgraduate medicine, 1991, Volume: 90, Issue:1 Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline	1991
Hypersexuality with antiparkinsonian therapy. Clinical neuropharmacology, 1989, Volume: 12, Issue:5 Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors; Sexual Behavior	1989
[Therapeutic strategies and tactics in parkinsonism]. Wiener medizinische Wochenschrift (1946), 1986, Aug-31, Volume: 136, Issue:15-16 Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders	1986
Parkinson's disease in the elderly: current management strategies. Geriatrics, 1987, Volume: 42, Issue:7 Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1987
Drugs for parkinsonism. The Medical letter on drugs and therapeutics, 1988, Dec-16, Volume: 30, Issue:781 Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline	1988
Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1984, Volume: 11, Issue:1 Suppl Topics: Adrenergic beta-Antagonists; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine; Dopamine Antagonists; Humans; Lithium; Neurology; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Selegiline; Serotonin; Sympathomimetics	1984
[Initiation of treatment in Parkinson disease]. Praxis, 1995, Sep-19, Volume: 84, Issue:38 Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline	1995
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease. Clinical neurology and neurosurgery, 1995, Volume: 97, Issue:2 Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome	1995
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. Journal of neural transmission. General section, 1994, Volume: 98, Issue:1 Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline	1994
Evaluation of chronic neurological sequelae after acute pesticide exposure using SPECT brain scans. Journal of toxicology and environmental health, 1994, Volume: 41, Issue:3 Topics: Adult; Amantadine; Brain; Carbidopa; Cerebrovascular Circulation; Cholinesterase Inhibitors; Female; Humans; Neurologic Examination; Pesticides; Selegiline; Tomography, Emission-Computed, Single-Photon	1994
Current therapy of Parkinson's disease. Iowa medicine : journal of the Iowa Medical Society, 1997, Volume: 87, Issue:1 Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Patient Selection; Selegiline	1997
A frequency and correlation analysis of motor deficits in Parkinson patients. Disability and rehabilitation, 1998, Volume: 20, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prognosis; Psychomotor Disorders; Psychomotor Performance; Selegiline; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Time Factors	1998
Seeking ways to crack cocaine addiction. Lancet (London, England), 1998, Oct-17, Volume: 352, Issue:9136 Topics: Amantadine; Clinical Trials as Topic; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Ibogaine; Methylphenidate; Selegiline	1998
Freezing of gait in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline	2001
[Therapy for patients with early-stage Parkinson's disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8 Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl	2003
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology, 2005, Mar-08, Volume: 64, Issue:5 Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome	2005
Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology, 2006, May-09, Volume: 66, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Databases, Factual; Dementia; Dopamine Agonists; Drug Prescriptions; Drug Utilization; Geriatrics; Humans; Levodopa; Male; Medicine; Middle Aged; Neurology; Northwestern United States; Parkinson Disease; Practice Patterns, Physicians'; Primary Health Care; Psychiatry; Psychology; Retrospective Studies; Selegiline; Specialization; United States; United States Department of Veterans Affairs; Veterans	2006
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs. Metabolic brain disease, 2009, Volume: 24, Issue:4 Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain Diseases; Cell Line, Tumor; Clorgyline; Endocytosis; Exocytosis; Hydrogen-Ion Concentration; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organelles; Pargyline; Parkinson Disease; Protons; Selegiline; Signal Transduction; Transport Vesicles	2009
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Ideggyogyaszati szemle, 2008, Jan-30, Volume: 61, Issue:1-2 Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome	2008
In vitro interactions of amantadine hydrochloride, R-(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection. Acta biologica Hungarica, 2012, Volume: 63, Issue:4 Topics: Amantadine; Amphotericin B; Antifungal Agents; Central Nervous System Fungal Infections; Drug Interactions; Fungi; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Selegiline; Terbinafine; Valproic Acid	2012
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Irish medical journal, 2013, Volume: 106, Issue:1 Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline	2013
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PloS one, 2014, Volume: 9, Issue:1 Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine Agents; Hallucinations; Humans; Illusions; Levodopa; Logistic Models; Multivariate Analysis; Parkinson Disease; Psychotic Disorders; Risk Factors; Selegiline; Surveys and Questionnaires	2014